{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-086074","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.108124+00:00","generated_at":"2026-05-31T12:48:16.154595+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEXX Q2 rev +6% to $1,004M; EPS $2.44; cuts FY guidance on litigation charge","bullets":["Revenue $1,004M, +6% reported (+7% organic); CAG Diagnostics recurring +6% reported (+7% organic).","EPS $2.44, down 9% reported; comparable +15% excluding $0.56/share discrete litigation accrual.","Record Q2 premium instrument placements; global premium instrument installed base grew 11% YoY.","FY2024 guidance updated: revenue $3,885M-$3,945M (6.2-7.8% organic); EPS $10.31-$10.59, down $0.56 at midpoint.","$62M discrete litigation expense accrual hit operating margin by ~610 bps and EPS by $0.56."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-086074","json":"https://secwatch.observer/filing/0001104659-24-086074.json","markdown":"https://secwatch.observer/filing/0001104659-24-086074.md","text":"https://secwatch.observer/filing/0001104659-24-086074.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000110465924086074/0001104659-24-086074-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000110465924086074/tm2420913d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:48:16.154595+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}